home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Pier Shareware 6
/
The_Pier_Shareware_Number_6_(The_Pier_Exchange)_(1995).iso
/
026
/
med9410a.zip
/
M94A0090.TXT
< prev
next >
Wrap
Text File
|
1994-10-01
|
3KB
|
43 lines
Document 0090
DOCN M94A0090
TI Phase I/II vaccination study of recombinant peptide F46 corresponding to
the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP)
Ficoll.
DT 9412
AU Schwander S; Opravil M; Luthy R; Hanson DG; Schindler J; Dawson A;
Letwin B; Dietrich M; Case Western Reserve University, School of
Medicine, Cleveland,; Ohio 44106.
SO Infection. 1994 Mar-Apr;22(2):86-91. Unique Identifier : AIDSLINE
MED/94350512
AB In order to evaluate tolerance, toxicity, and in vivo antigenicity, 29
HIV-1-infected patients (eight with ARC and 21 with AIDS) were
vaccinated with a synthetic peptide derived from the gp41 transmembrane
protein of the HIV-1. This peptide had been coupled with 2.4
dinitrophenyl-Ficoll (F46), a T-cell independent adjuvant. The patients
received a single intradeltoid injection of either 0.1 or 0.3 mg of F46.
Five of the individuals with AIDS were boostered, four of them twice.
Anti-F46 antibody titers were measured before vaccination, and on days
7, 14, 21, 28, 90, 180 and 270 after vaccination. Anti-F46 titers rose
at least twofold over prestudy values in 10/21 individuals with AIDS and
in 1/8 individuals with ARC at least once during the observation period.
The overall response, however, consisted of only weak antibody
production that was independent of the dose or patient characteristics.
No signs of toxicity or of clinical progression related to the
vaccination were observed in this phase I/II trial of a T-cell
independent therapeutic vaccine.
DE Acquired Immunodeficiency Syndrome/BLOOD/IMMUNOLOGY/*THERAPY Adjuvants,
Immunologic/*THERAPEUTIC USE Adult Antigens/*IMMUNOLOGY AIDS
Vaccines/*THERAPEUTIC USE AIDS-Related
Complex/BLOOD/IMMUNOLOGY/*THERAPY Female Ficoll/*ANALOGS &
DERIVATIVES/IMMUNOLOGY Human HIV Antibodies/BLOOD HIV Envelope
Protein gp41/*IMMUNOLOGY *HIV-1/IMMUNOLOGY Immunization,
Secondary/METHODS Injections, Intramuscular Leukocyte Count Male
Middle Age Recombinant Proteins/*THERAPEUTIC USE Support, Non-U.S.
Gov't *T4 Lymphocytes Vaccines, Synthetic/*THERAPEUTIC USE CLINICAL
TRIAL CLINICAL TRIAL, PHASE I CLINICAL TRIAL, PHASE II JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).